Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins
US5783181A · kind A · utility
69Cited by
1References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 6, 1995 |
| Grant date | Jul 21, 1998 |
| Priority date | — |
| Expiry date | Jun 6, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity comprises an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.